Superworth

Nurix Therapeutics free cash flow NRIX

Cash from operations less capital spending, by quarter and over the last twelve months, from 2019.

Last 12 months, to Aug 31, 2026
$369.8M
Latest quarter, Q3 FY26
$614.2M
Fiscal year 2025
−$263.5M

Nurix Therapeutics' free cash flow was $369.8M over the twelve months to Aug 31, 2026.

In its latest quarter, Q3 FY26, it was $614.2M.

Free cash flow over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearFree cash flowChange
FY2025−$263.5Mn/a
FY2024−$181.9Mn/a
FY2023−$89.8Mn/a
FY2022−$172.1Mn/a
FY2021−$90Mn/a
FY2020−$4.6Mn/a
FY2019n/an/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedFree cash flowOn a year earlierLast 12 months
Q3 FY26$614.2Mn/a$369.8M
Q2 FY26−$98.5Mn/a−$304.5M
Q1 FY26−$73Mn/a−$271.9M
Q4 FY25−$73Mn/a−$263.5M
Q3 FY25−$60.1Mn/a−$241.4M
Q2 FY25−$65.8Mn/a−$225.8M
Q1 FY25−$64.6Mn/a−$201.6M
Q4 FY24−$50.9M−311%−$181.9M
Q3 FY24−$44.5Mn/a−$106.9M
Q2 FY24−$41.6Mn/a−$106M
Q1 FY24−$44.8Mn/a−$83.9M
Q4 FY23$24.1Mn/a−$89.8M

Against its peers

Companies in Drug Manufacturers - General nearest Nurix Therapeutics' size, closest first, today.

CompanyFree cash flow yield
NRIXNurix Therapeutics13.4%
PBHPrestige Consumer Healthcare10.4%
OGNOrganon15.7%
HRMYHarmony Biosciencesn/m
LQDALiquidia3.9%
ARQTArcutis Biotherapeutics1.0%
INDVIndivior Pharmaceuticals−2.7%
ANIPANI Pharmaceuticals10.4%
PAHCPhibro Animal Health0.6%
ANABAnaptysbion/m
PCRXPacira BioSciences12.4%
Peer median7.2%

Where Nurix Therapeutics ranks

What the free cash flow tells you

Cash from operations minus capital spending. The cash the company could hand back or reinvest.

Seasonal and lumpy quarter to quarter. The TTM view is the one to trust.

More on Nurix Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.